← Browse by Condition
Medical Condition
hepatocellular carcinoma hcc
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 2, Phase 3, Phase 1
ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma hcc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — hepatocellular carcinoma hcc Clinical Trials
How many clinical trials are currently recruiting for hepatocellular carcinoma hcc?
ClinicalMetric currently tracks 12 actively recruiting clinical trials for hepatocellular carcinoma hcc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hepatocellular carcinoma hcc?
hepatocellular carcinoma hcc research spans Phase 1 (2 trials), Phase 2 (3 trials), Phase 3 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hepatocellular carcinoma hcc clinical trial?
Eligibility criteria for hepatocellular carcinoma hcc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 3
Phase 3 1
Phase 4 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07327034 Phase 2
Recruiting
Enrollment
141 pts
Location
China
Sponsor
Abbisko Therapeutics Co, Ltd
NCT07186621 Phase 3
Recruiting
Enrollment
286 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
NCT07419841 Phase 1
Recruiting
Enrollment
70 pts
Location
United States
Sponsor
Compass Therapeutics
NCT07101237
Recruiting
Enrollment
308 pts
Location
China
Sponsor
Peking Union Medical College H...
NCT05824975 Phase 1, Phase 2
Recruiting
Enrollment
358 pts
Location
United States, South...
Sponsor
GI Innovation, Inc.
NCT07192185 Phase 2
Recruiting
Enrollment
30 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07658833
Recruiting
Enrollment
120 pts
Location
China
Sponsor
Sun Yat-Sen Memorial Hospital ...
NCT07150624 Phase 4
Recruiting
Enrollment
96 pts
Location
China
Sponsor
Anhui Provincial Hospital
NCT06961526
Recruiting
Enrollment
110 pts
Location
Egypt
Sponsor
Tanta University
NCT06914648
Recruiting
Enrollment
358 pts
Location
United States, Austr...
Sponsor
Maastricht University
NCT07677774
Recruiting
Enrollment
40 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07059936
Recruiting
Enrollment
350 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
Related Conditions
renal cell carcinoma rcc (2) primary liver cancer (2) radiotherapy adjuvant (1) immune checkpoint inhibitor (1) tace (1) narrow margin (1) gastroesophageal cancer gc (1) endometrial cancer (1) intrahepatic cholangiocarcinoma icc (1) advanced solid tumor (1) metastatic solid tumor (1) soft tissue sarcoma sts (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology